Efficacy, Tolerability and Safety of Nateglinide in Combination with Metformin. Results from a Study under General Practice Conditions

Abstract

In a general practice observation study 11 476 patients with type 2 diabetes pretreated with oral antidiabetic drugs, mainly metformin, received an oral combination therapy of nateglinide with metformin. Mean age ± SD of the participants was 61 ± 10.3 years, range 19 to 97 years, the body mass index (mean ± SD) was 29.4 ± 4.5 kg/m², range 14.9 to 68.7 kg/m². The observation period lasted 3 to 4 months (mean 96 days). During this period the mean HbA_1c decreased from 8.4 % to 7.2 %, displaying a positive relation between initial value and degree of reduction. Postprandial glucose levels dropped from a mean of 210 to 152 mg/dl. At the beginning of the study the combination of the two target values for glucose control, HbA_c < 7 % and postprandial glucose < 180 mg/dl, was reached in only 5.8 % of the participants, at the end in 44.9 %. During the therapy, weight and blood pressure dropped slightly. Adverse events were reported in only 2.9 % of the patients and involved a broad range of symptoms with mild gastrointestinal complaints being predominant (1.3 %). This study demonstrated that the combination of nateglinide with metformin can be considered as an effective and safe option for treatment of patients with type 2 diabetes, with additional beneficial effects on body weight and blood pressure.

Nateglinide - metformin - general practice study - safety - tolerability

References

• 1 Füchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 2000;  108 151-163
• 2 Halas C J. Nateglinide.  Am J Health-Syst Pharm. 2001;  58 1200-1205
• 3 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
• 4 Hanif W, Kumar S. Nateglinide: a new rapid-acting insulinotropic agent.  Expert Opin Pharmacother. 2001;  2 1027-1031
• 5 Horton E S, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.  Diabetes Care. 2000;  23 1660-1665
• 6 Keilson L, Mather S, Walter Y H, Subramanian S, McLeod J F. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2000;  85 1081-1086
• 7 Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes.  Diabetes Care. 1995;  18 258-268
• 8 Marre M, Whatmough I, Ball M, Guitard C. Nateglinide added to metformin offers safe and effective treatment for type 2 diabetes.  Diabetes. 2000;  49 (Suppl1) 1517
• 9 Nationale Versorgungs-Leitlinie Diabetes mellitus Typ . http://www.leitlinien.de/versorgungsleitlinien/index/diabetes/pdf/nvldiabetes . 2002
• 10 The Research Group D CCT. The relationship of glycemic exposure (HbA_1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.  Diabetes. 1995;  44 968-983
• 11 The study group D ECODE. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe.  Lancet. 1999;  354 617-621
• 12 Prospective Diabetes Study Group U K(UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853